How GLP-1 Drugs Are Changing Vacation Planning

When Food Isn't the Point Anymore

For decades, food dictated how we traveled. You'd lock in trattoria reservations months in advance, build entire afternoons around street markets, and treat local bakeries like essential sights. Now, that familiar rhythm is starting to unravel.

Blame—or credit—the rise of GLP-1 receptor agonists. Millions are taking these drugs, and they don't just blunt hunger; they quiet the brain's background chatter around food, temptation, and downtime. When you no longer care about a mid-afternoon pastry or a heavy four-course dinner, the whole architecture of a trip starts to wobble.

Reclaiming the Hours Between Meals

Consider what happens to a vacation when dining isn't the main event. That prepaid cooking class suddenly feels more like an obligation than a highlight. All-inclusive resorts lose their value pretty quickly if you're leaving half your plate untouched. Even killing time in an airport lounge feels weird when mindless grazing isn't on the table.

Instead of losing whole afternoons to heavy lunches and food comas, travelers are getting hours of their day back. They aren't spending three hours hunting down a hyped-up gelateria—they're booking active day trips, hiking further, and seeing destinations through a totally different lens. It's a shift the travel industry won't be able to ignore for long.

Has Your Itinerary Shifted?

The New York Times wants to hear directly from travelers navigating this new reality. If you're taking a GLP-1 medication and it's reshaped how you book, structure, or experience your trips, they want your perspective.

Did these medications take the anxiety out of holiday eating, or make dining out abroad a bit of a puzzle? Maybe you scrapped a food-focused cruise, or finally had the stamina to tackle a grueling mountain trek without running on empty. Whatever you've noticed, your story is helping shape this conversation, and it's only just beginning.